Journal
BRITISH JOURNAL OF CANCER
Volume 103, Issue 8, Pages 1139-1143Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.bjc.6605912
Keywords
drug resistance; evolution; genomic instability; heterogeneity
Categories
Funding
- MRC [G0902275] Funding Source: UKRI
- Medical Research Council [G0902275] Funding Source: researchfish
- Cancer Research UK Funding Source: Medline
- Medical Research Council [G0902275] Funding Source: Medline
Ask authors/readers for more resources
Carcinogenesis is an evolutionary process that establishes the 'hallmarks of cancer' by natural selection of cell clones that have acquired advantageous heritable characteristics. Evolutionary adaptation has also been proposed as a mechanism that promotes drug resistance during systemic cancer therapy. This review summarises the evidence for the evolution of resistance to cytotoxic and targeted anti-cancer drugs according to Darwinian models and highlights the roles of genomic instability and high intra-tumour genetic heterogeneity as major accelerators of this evolutionary process. Clinical implications and strategies that may prevent the evolution of resistance or target the origins of genetic heterogeneity are discussed. New technologies to measure intra-tumour heterogeneity and translational research on serial biopsies of cancer lesions during and after therapeutic intervention are identified as key areas to further the understanding of determinants and mechanisms of the evolution of drug resistance. British Journal of Cancer (2010) 103, 1139-1143. doi:10.1038/sj.bjc.6605912 www.bjcancer.com Published online 28 September 2010 (C) 2010 Cancer Research UK
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available